53
Participants
Start Date
November 28, 2019
Primary Completion Date
January 9, 2024
Study Completion Date
May 31, 2025
Recombinant Humanized Monoclonal Antibody MIL62 Injection
1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).
Lenalidomide
Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction
RECRUITING
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
Beijing Mabworks Biotech Co., Ltd.
INDUSTRY